Latest From Ablexis LLC
Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.
Antibody platform play Ablexis has successfully built its technology, fulfilled a commitment to its pharmaceutical partners, triumphed in a lawsuit brought by one of biotech’s big boys, and lined the pockets of its investors. Surprisingly, it has no imitators.
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Ablexis LLC
- Senior Management
Larry Green, PhD, CEO
Richard Hoffman, Chief Business Officer
Sean Stevens, PhD, VP, Research
- Contact Info
Phone: (415) 967-1220
San Francisco, CA
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.